Related Experiment Video
Updated: Aug 8, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
Activated protein C resistance--low incidence in glaucomatous optic disc haemorrhage and central retinal vein
S L Graham1, I Goldberg, B Murray
1Department of Ophthalmology, Prince of Wales Hospital, Sydney, NSW.
Purpose:
Activated protein C (APC) resistance has recently been reported as conferring a sevenfold increase in the risk of venous thrombosis. It is linked to a genetic mutation in the factor V gene which occurs commonly (about 2% to 4% of the community have the mutation). Glaucoma patients with nerve fibre layer (NFL) haemorrhages on the optic disc and patients with central retinal vein occlusion (CRVO) were tested for APC resistance to determine if there was an association.
Methods:
Twenty-three patients with glaucomatous NFL haemorrhages and 23 patients with CRVO were tested. The CRVO cases included 11 with relatively young age of onset (mean 45.1 +/- 6.9 years) without conventional vascular risk factors. Eighty randomly selected Red Cross blood donor samples and 33 staff members were tested as controls. Clotting times with and without exogenous APC were recorded and an APC ratio determined. Cases with APC resistance were tested to confirm that they had the factor V Leiden gene.
Results:
No cases of APC resistance were identified in the glaucoma patients and only one of the younger CRVO patients tested positive, but four of 113 controls tested positive. The difference in prevalence between groups is not significant. The mean APC ratios for the three groups were very similar: NFL haemorrhages 5.46(+/- 1.62), CRVO 5.70(+/- 1.56), controls 5.34 ( +/- 1.19) p > 0.5.
Conclusion:
There was not clear association detected between glaucomatous NFL haemorrhages or CRVO and APC resistance in this sample of patients. This negative finding is important due its known association with venous thrombosis elsewhere in the body.
Insights
Activated protein C (APC) resistance, a risk factor for venous thrombosis, was investigated in glaucoma patients with nerve fibre layer hemorrhages and central retinal vein occlusion (CRVO). No significant association was found between these conditions and APC resistance.
Area of Science:
- Ophthalmology
- Hematology
- Genetics
Background:
- Activated protein C (APC) resistance is a known risk factor for venous thrombosis.
- This resistance is often linked to the factor V Leiden gene mutation, prevalent in 2-4% of the general population.
- Ocular vascular conditions like glaucoma with nerve fibre layer (NFL) hemorrhages and central retinal vein occlusion (CRVO) warrant investigation for potential thrombotic links.
Purpose of the Study:
- To determine if a significant association exists between glaucomatous NFL hemorrhages or CRVO and activated protein C (APC) resistance.
- To investigate the prevalence of APC resistance in patients with specific ocular vascular conditions.
Main Methods:
- A case-control study involving 23 patients with glaucomatous NFL hemorrhages and 23 with CRVO (including 11 young-onset cases).
- Control groups included 80 blood donors and 33 staff members.
- Activated protein C (APC) resistance was assessed by measuring clotting times and calculating APC ratios; factor V Leiden gene testing was performed for positive cases.
Main Results:
- No APC resistance was detected in glaucoma patients.
- Only one young-onset CRVO patient tested positive for APC resistance.
- The prevalence of APC resistance in the patient groups was not significantly different from the control groups (4 out of 113 controls tested positive).
Conclusions:
- This study did not find a clear association between glaucomatous NFL hemorrhages or CRVO and activated protein C (APC) resistance.
- The negative finding is significant given the established link between APC resistance and venous thrombosis.
- Further research may be needed to fully elucidate the relationship between thrombophilia and ocular vascular diseases.
Related Concept Videos
Glaucoma: Overview
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Diabetic Retinopathy

